Medicare Enrolled

Dr. Michael Adler, M.D.

Endocrinology · Lewisburg, PA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
80 MEDICAL PARK DR, Lewisburg, PA 17837
5707684646
In practice since 2006 (20 years)
NPI: 1568432136 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Adler from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Adler? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Adler

Dr. Michael Adler is an endocrinology specialist in Lewisburg, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Adler performed 2,414 Medicare services across 921 unique beneficiaries.

Between the years covered by Open Payments, Dr. Adler received a total of $326,526 from 50 pharmaceutical and/or device companies across 1175 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Adler is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 15% volume in PA $326,526 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,414
Medicare services
Top 15% in PA for endocrinology
921
Unique beneficiaries
$40
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~121 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 960 $19 $91
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
629 $61 $157
Continuous glucose monitoring with interpretation
This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results.
266 $24 $76
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
264 $80 $194
Diabetes self-management training, individual
Individualized education and training for managing diabetes, billed per 30-minute session.
177 $42 $116
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
52 $73 $220
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
36 $8 $15
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
17 $10 $39
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
13 $106 $297
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$326,526
Total received (2018-2024)
Avg $46,647/year across 7 years
Top 4% in PA for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
1,175
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$315,806 (96.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,983 (2.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,738 (1.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$16,736
2023
$34,978
2022
$54,216
2021
$50,610
2020
$56,769
2019
$48,365
2018
$64,851

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$6,862
ABBVIE INC.
$3,165
Lilly USA, LLC
$2,976
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,504
Amgen Inc.
$204
SANOFI-AVENTIS U.S. LLC
$158
AstraZeneca Pharmaceuticals LP
$93
Averitas Pharma Inc.
$80
Dexcom, Inc.
$64
Abbott Laboratories
$58
Novartis Pharmaceuticals Corporation
$56
CeQur Corporation
$55
Insulet Corporation
$50
Alexion Pharmaceuticals, Inc.
$48
Tolmar, Inc.
$48
IBSA Pharma Inc.
$42
Kyowa Kirin, Inc.
$41
Antares Pharma, Inc.
$38
Tandem Diabetes Care, Inc.
$37
Bayer Healthcare Pharmaceuticals Inc.
$34
Corcept Therapeutics
$33
Xeris Pharmaceuticals, Inc.
$33
PFIZER INC.
$22
Esperion Therapeutics, Inc.
$18
Radius Health, Inc.
$16
Top 3 companies account for 77.7% of 2024 payments
All-time payments by company (2018-2024) ›
Novo Nordisk Inc
$139,326
Lilly USA, LLC
$109,654
Boehringer Ingelheim Pharmaceuticals, Inc.
$26,610
AbbVie, Inc.
$16,195
SANOFI-AVENTIS U.S. LLC
$11,997
AbbVie Inc.
$8,033
ABBVIE INC.
$4,108
Eli Lilly and Company
$3,738
AstraZeneca Pharmaceuticals LP
$1,075
Tandem Diabetes Care, Inc.
$861
Amgen Inc.
$861
Abbott Laboratories
$444
Dexcom, Inc.
$433
Janssen Pharmaceuticals, Inc
$311
Novartis Pharmaceuticals Corporation
$227
Radius Health, Inc.
$201
Bayer HealthCare Pharmaceuticals Inc.
$183
Insulet Corporation
$183
Merck Sharp & Dohme Corporation
$167
PFIZER INC.
$163
IBSA Pharma Inc.
$129
Xeris Pharmaceuticals, Inc.
$129
Corcept Therapeutics
$129
Shire North American Group Inc
$107
MannKind Corporation
$106
Ascendis Pharma Inc
$106
Alexion Pharmaceuticals, Inc.
$102
Valeritas, Inc.
$87
Averitas Pharma Inc.
$80
Ultragenyx Pharmaceutical Inc.
$71
CeQur Corporation
$71
Bayer Healthcare Pharmaceuticals Inc.
$68
Antares Pharma, Inc.
$68
OPKO Pharmaceuticals, LLC
$54
Zealand Pharma US, Inc.
$50
Supernus Pharmaceuticals, Inc.
$49
Tolmar, Inc.
$48
Merck Sharp & Dohme LLC
$47
Kyowa Kirin, Inc.
$41
Medtronic MiniMed, Inc.
$34
Amarin Pharma Inc.
$30
DEXCOM, INC.
$23
EISAI INC.
$20
Medtronic, Inc.
$19
AKRIMAX PHARMACEUTICALS, LLC
$18
Esperion Therapeutics, Inc.
$18
Gilead Sciences, Inc.
$15
Clarus Therapeutics Inc.
$14
Hologic, LLC
$14
BioDelivery Sciences International, Inc.
$11
Top 3 companies account for 84.4% of all-time payments
Associated products mentioned in payments ›
AFREZZA · Androgel · BAQSIMI · BASAGLAR · BUNAVAIL 2.1 mg 30-count box · BYDUREON · COSENTYX · CeQur Simplicity · Crysvita · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · DEXCOM G6 TRANSMITTER · Dexcom CGM · Dexcom G6 Transmitter · ENTRESTO · EVENITY · FARXIGA · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre 2 · FreeStyle Libre blood glucose Flash Monitoring System · GVOKE HYPOPEN · GVOKE PFS · HUMULIN · INVOKANA · JANUVIA · JARDIANCE · JATENZO · Kerendia · Korlym · LEQVIO · LICART · LINZESS · LYUMJEV · Lenvima · Levemir · MINIMED 780G · MOUNJARO · Minimed 670G System · NATPARA · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NOCDURNA · OMNI · Omnipod · Ozempic · Prolia · QUTENZA · RECORLEV · RYBELSUS · Rayaldee · Repatha · Rybelsus · SOLIQUA · SOLIQUA 100/33 · SOMAVERT · STEGLATRO · STRENSIQ · SYNJARDY · SYNTHROID · Saxenda · Stendra · Synthroid · TLANDO · TOUJEO · TRADJENTA · TRULICITY · TZIELD · Tirosint · Tresiba · Tymlos · V-GO · Vascepa · Victoza · Wegovy · XARELTO · XYOSTED · Xultophy 100/3.6 · ZEGALOGUE · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ · t:slim X2 insulin pump
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (97%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for endocrinology in PA.

Looking for an endocrinology specialist in Lewisburg?
Compare endocrinologists in the Lewisburg area by procedure volume, costs, and industry payment transparency.
Browse endocrinologists nearby

Geographic Context

Endocrinologists within 10 mi
10
Per 100K population
23.5
County median income
$72,894
Nearest hospital
WELLSPAN EVANGELICAL COMMUNITY HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Adler is a clinical cardiology specialist, with above-average Medicare volume (top 15% in PA), with speaking/promotional industry engagement in the top 4% of PA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Adler experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Adler performed 960 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Adler receive payments from pharmaceutical companies?
Yes. Dr. Adler received a total of $326,526 from 50 companies across 1,175 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Adler's costs compare to other endocrinologists in Lewisburg?
Dr. Adler's average Medicare payment per service is $40. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Adler) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →